POSTER ABSTRACT
Purpose
Total ankle arthroplasty (TAA) remains a viable alternative to ankle arthrodesis. The latest generation of TAA implant designs emphasize minimal bone resection and anatomic preservation. We have previously described our adapted technique combining an intramedullary tibial component with a minimal resection chamfer-cut talar component. The purpose of the present study is to report our short-term clinical outcomes with this hybrid technique.
Procedure
We performed a retrospective case series of consecutive patients undergoing primary TAA using this hybrid implant with a minimum of two-years follow up. Primary outcomes included the Visual Analog Pain Scale (VAS) and the American Orthopedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Scale. Secondary outcomes included rates of associated complications, reoperations, and revisions.
Results
Thirty-three consecutive patients (42% male, average age 59 years) met the inclusion criteria with an average follow up of 36 months. VAS improved from 7.1 preoperatively to 1.1 postoperatively (p<0.0001). Similarly, AOFAS scores improved from 42.2 preoperatively to 90.7 postoperatively (p<0.0001). Fifteen patients had a postoperative complication (45%), with 13 requiring a reoperation (39%), and 1 requiring a revision (3%).
Discussion
We found statistically significant improvement in patient-reported outcomes postoperatively with the majority of our complications being low-grade. At an average follow up of 3 years, implant survivorship was 97%. We demonstrate overall positive short-term clinical and radiographic outcomes of a novel hybrid TAA technique combining an intramedullary tibial component and a chamfer-cut talar component.
ACFAS ASC 2023
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Appendix. Supplementary materials
Article info
Publication history
Accepted:
March 6,
2023
Received:
March 4,
2023
Publication stage
In Press Accepted ManuscriptIdentification
Copyright
User license
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) | How you can reuse 
Elsevier's open access license policy
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy
